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Summary In a consecutive series of studies, 164 patients with symptomatic and/or visceral metastatic
malignant melanoma were treated with single agent vindesine, high dose melphalan with autologous bone
marrow transplantation (ABMT), high dose BCNU with ABMT or the BOLD (bleomycin, vincristine, CCNU
and DTIC) combination. The high dose treatments and the combination chemotherapy resulted in significantly
higher response rates but no prolongation of survival. Factors associated with longer survival included the
absence of visceral metastases, the absence of bulky disease and good performance status. For all treatments,
life table estimates of survival at I and 2 years were only 10% and 4% respectively.
Although the results of chemotherapy for malignant mela-
noma vary between institutions and according to the criteria
used to evaluate response, it is well recognised that its effi-
cacy is disappointing. In order to improve on these results,
several possible avenues have been open for exploration.
First the dosage of drugs can be escalated. Using this ap-
proach, we have used high dose melphalan (HDM) and high
dose BCNU (HDBCNU) with autologous bone marrow
transplantation. The second avenue is the use of chemo-
therapeutic agents in combination. Claims for improved res-
ponses in the treatment of malignant melanoma have been
made with the use of drug combinations (Voight & Kleeberg,
1984; Abele et al., 1981; Cohen et al., 1986; Bajetta et al.,
1985) particularly the BOLD and related regimens (bleo-
mycin, vincristine, CCNU and DTIC) (Siegler et al., 1980;
Young et al., 1985). In our institution over the past decade
we have sequentially studied the value of single agent
chemotherapy in conventional dose (vindesine, VDN), high
dose chemotherapy (HDM, HDBCNU) and most recently
combination chemotherapy (BOLD), and we report and com-
pare these studies here.
Methods and patients
Study method
One of us (S.L.) carried out a retrospective analysis of all
patients treated between 1976 and 1986 with one of the four
treatment schedules (VDN, HDM, HDBCNU, BOLD).
Throughout the study we have followed the principle that
metastatic malignant melanoma should only be treated with
chemotherapy if it is causing symptoms or threatening life.
For this reason the patients were treated with chemotherapy
only if they had symptomatic metastatic disease or they had
progressive visceral metastases whether symptomatic or not.
Patients with asymptomatic cutaneous or subcutaneous dis-
ease alone were not given chemotherapy. A consistent policy
for indications for treatment and criteria of response has
been used throughout the study. The study was a sequential
one and the regimens were exchanged and new programmes
started as the lack of efficacy became apparent.
Staging tests
Patients had full blood count, urea, creatinine, serum elect-
rolytes and hepatic enzymes measured before each course of
chemotherapy. Initial staging investigations also included a
CXR and liver scan (isotope or ultrasound), which was
repeated to assess response or verify suspicion of new disease
as indicated.
Statistical methods
Analysis of variance and standard x2 techniques were used
for treatment group comparison. Logistic regression techni-
ques with standard forward selection methods were used to
determine factors predictive of response. Estimates of odds
ratios (OR) and their 95% confidence intervals (CI) are
given. The log rank test and Cox proportional hazards re-
gression methods using forward selection were implemented
for analysis of survival data (Peto et al., 1977; Cox & Oakes,
1984), and odds ratio (OR) estimates and their 95%
confidence intervals (CI) are shown.
When considering response to treatment as a possible
prognostic indicator of survival two approaches were exam-
ined: (i) inclusion of all patients; (ii) exclusion of those who
may have survived long enough to respond to treatment. A
period of 3 months from the start of treatment was taken for
the exclusion. Of the patients who responded, 83% (19/23)
did so within this period.
Treatment details
Vindesine VDN was administered as a slow intravenous
injection at a dose of 3 mg m-2 and was repeated at weekly
intervals. Treatment was delayed if the WBC was < 3.0
x I09 1 ' or if the platelet count fell to < 100 x I09 1-'. We
aimed to give at least four treatments before assessing im-
provement. Progression during that time or severe toxicity
(any toxicity greater than WHO grade 2, except for hair loss
for which grade 3 toxicity was not regarded as a reason to
stop VDN) were reasons to discontinue the drug. Patients
who improved were treated to maximum response (or
limiting toxicity).
HDM The full details of this treatment are given by Corn-
bleet et al. (1983). Melphalan was given in a dose of
140-260 mg m-2. Cyclophosphamide priming was used in
most of the patients at a dose of 300 mg m-2 i.v. and was
administered 7 days before treatment with melphalan. On the
day of treatment approximately 2 x 108 nucleated bone mar-
row cells per kg were harvested, heparinised and stored at
4°C. Melphalan was given as a bolus injection via a central
line with i.v. fluids to ensure a urine output of > 200 ml h-'
for the following 8 h. The bone marrow was reinfused peri-
pherally 8-14 h after the administration of melphalan.
Patients who achieved a partial response on this regimen
were considered for further high dose chemotherapy as a
consolidation treatment, but only after a convalescent period
of at least 6 weeks. Subsequent courses of HDM were given
at a dose of 140 mg m-2. Four patients received a further
course.
Correspondence: P. Selby, Institute for Cancer Studies, St James's
University Hospital, Beckett Street, Leeds LS9 7TF, UK.
Received 16 March 1989; and in revised form 5 October 1989.
Br. J. Cancer (1990), 61, 330-334 'PI Macmillan Press Ltd., 1990
CHEMOTHERAPY FOR MALIGNANT MELANOMA 331
HDBCNU BCNU was given at a dose of 800 mg m2 dis-
solved in 12 ml of alcohol solvent (Mbidde et al., 1988). The
autologous bone marrow transplant (ABMT) was carried out
as for HDM. The bone marrow was cryopreserved and re-
infused 48 h after the administration of BCNU. As with
HDM, one patient who achieved a partial response received
further treatment with HDBCNU.
BOLD The BOLD combination chemotherapy regimen em-
ployed in our patients consists of the following: bleomycin
15 mg i.v. on day I and day 4; vincristine (Oncovin)
1 mgm-2 i.v. day 1; DTIC 200mgm-2 i.v. days 1-5 in-
clusive; CCNU (Lomustine) 80 mg m-2 orally day 3 with
each alternate course.
The treatment is repeated every 4 weeks. The treatment
was deferred if the Hg < 9 g 1-', the WBC < 2 x 109 1-l or
the platelets <100 x 109 dl-'. Our aim was to give a mini-
mum of two treatments and to continue only in patients who
showed some tumour volume reduction or symptomatic im-
provement after two treatments. Progressive disease on one
treatment was regarded as sufficient evidence of lack of effect.
Eight patients received only one course: five had rapidly
progressive disease, one severe side-effects, one patient with
visceral disease died before his second course and one patient
went abroad without finishing his treatment.
Patients
One hundred and sixty-four patients who had received no
previous chemotherapy were treated with one of the four
chemotherapy regimens outlined above and their characteris-
tics are given in Table I. Analysis of variance indicates that
the ages of patients are not comparable across treatment
regimens. Patients receiving VDN are slightly older than
those on both HDM and HDBCNU. The treatment groups
appear to be otherwise comparable.
The principal primary site of tumour was the limbs (42%).
Of the 34 patients in the 'other' group, seven had no known
primary site and these patients were thought to have spon-
taneously regressing primary melanomas. A large proportion
of the patients treated had either lymph nodal and/or visceral
matastases and the chief indications for treatment were
asymptomatic progression or pain. Most of these patients
were graded as having performance status of less than 2. The
median time from development of first metastases to treat-
ment was 5.5 months and did not differ significantly between
groups.
Response criteria
We have used the WHO criteria (WHO, 1979) for evaluating
response. These are summarised below and our own ap-
proach to their application is indicated.
1. Complete response (CR) The disappearance of all known
disease, determined by two observations not less than 4
weeks apart. We have required that all investigations which
were abnormal before treatment return to normality.
2. Partial response (PR) Fifty per cent or more decrease in
total tumour size of all measurable lesions to determine the
effect of therapy by two observations not less than 4 weeks
apart. In addition there can be no appearance of new lesions
or progression of any lesion.
3. No change (NC) A 50% decrease in total tumour size
cannot be established nor has a 25% increase in the size of
one or more measurable lesions been demonstrated. In our
analysis we subdivided this group into those who had re-
ceived symptomatic improvement NC (I) and those who had
not NC (NI).
4. Progressive disease (PD) A 25% or more increase in size
of one or more measurable lesions, or the appearance of new
lesions. In the WHO criteria the term 'tumour size' is used.
We have taken this to mean the product of the two longest
measurable diameters of each mass, indicating its largest
Table I Patient characteristics
VDN HDM HDBCNU BOLD All patients
Age (years)
Median 50.1 35.7 33.3 46.4 45.1
Range
Min. 21.6 16.2 21.3 18.1 16.2
Max. 74.6 63.4 45.0 67.4 74.6
Sex
Male 36 (45%) 18 (53%) 5 (56%) 20 (49%) 79 (48%)
Female 44 (55%) 16 (47%) 4 (44%) 21 (51%) 85 (52%)
Median time Ist met. to 4.6 5.4 8.8 7.2 5.6
RX (months)
Primary site
Head/neck 6 ( 8%) 6 (18%) 0 ( 0%) 4 (10%) 16 (10%)
Trunk 24 (30%) 7 (21%) 1 (11%) 14 (34%) 46 (28%)
Limbs 34 (43%) 14 (41%) 4 (44%) 16 (39%) 68 (41%)
Others 16 (20%) 7 (21%) 4 (44%) 76 (17%) 34 (21%)
Metastases before I Rx
Nodal 11 (14%) 3 ( 9%) 3 (33%) 3 ( 7%) 20 (12%)
Skin 2 ( 3%) 0( 0%) 0( 0%) 0( 0%) 2 ( 1%)
Visceral 8 (10%) 5 (15%) 0 ( 0%) 7 (17%) 20 (12%)
Nodal/skin 12 (16%) 3 ( 9%) 0 ( 0%) 5 (12%) 21 (13%)
Nodal/visceral 13 (16%) 2 ( 6%) 3 (33%) 8 (20%) 26 (16%)
Skin/visceral 9 (11%) 5 (15%) 2 (22%) 5 (12%) 21 (13%)
Node/skin/visceral 24 (30%) 16 (47%) 1 (11%) 13 (32%) 54 (33%)
Indication for treatment
Asymp. prog. 27 (34%) 12 (35%) 3 (33%) 13 (32%) 55 (36%)
Pain 32 (40%) 15 (44%) 2 (22%) 21 (51%) 70 (43%)
Bulky nodes 6 ( 8%) 2 ( 6%) 1 (11%) 3 ( 7%) 12 ( 7%)
Others 15 (19%) 4 (12%) 3 (33%) 4 (10%) 27 (16%)
Performance status
0 32 (40%) 13 (38%) 2 (22%) 13 (32%) 60 (37%)
1 32 (40%) 13 (38%) 4 (44%) 24 (59%) 73 (45%)
2 13 (16%) 8 (24%) 0( 0%) 2( 5%) 23 (14%)
3/4 3 ( 4%) 0( 0%) 3 (33%) 2 (5%) 8 ( 5%)
Total patients 80 34 9 41 164
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cross-sectional area. Improvement in symptoms was only
judged retrospectively by recorded comments and not by
scaled estimates of symptom severity.
Results
Treatments administered
Table II shows the number of courses of the four treatments
administered. In the VDN group the majority of the patients
(71%) received four or more injections. In the BOLD group
80% of the patients received two or more courses. Twenty-
three patients in the VDN group and eight patients in the
BOLD group received less treatment than planned because of
progressive disease or toxicity. Of the patients who received
high dose chemotherapy, five went on to receive a second
course as a form of consolidation therapy and one patient
who had achieved a PR twice with HDM received a third
course.
Response and survival
The response rates for the four treatment regimens are shown
in Table III and the sites of disease for complete respond-
ers in Table IV. The response rates for each of HDM,
HDBCNU and BOLD are significantly greater in VDN
(P< 0.005). Figure 1 shows the comparison of the survival
of patients in each treatment regimen from the start of the
treatment. Despite the variations in response rates, there is
no difference in overall survival (log rank test = 0.17; d.f. = 3,
P = 0.98). Figure 2 shows the survival from time of treatment
for patients who responded to treatment compared with non-
responders. In Figure 2a, having included all patients, we
observe considerable evidence that responders live longer than
non-responders (log rank test (stratified by treatment)
= 11.37; d.f. = 1, P = 0.001). Having excluded patients as des-
cribed above who were not potentially eligible for a response
we observe in Figure 2b only marginal evidence that
responders live longer than non-responders (log rank test
(stratified by treatment) = 4.49; d.f. = 1, P = 0.034).
The median duration of remission for responders for all
treatments (time to progression from treatment) was 3
months and there is no difference between the treatments.
Toxicity
BOLD Table V shows the number of patients who experi-
enced toxicity of greater than grade 2 WHO criteria (e.g. Hb
<9.4gdl-', WBC <2.9 x 1091-', platelets <74x 1091-'
or mild transient or persistent vomiting requiring treatment).
The toxicity of the BOLD regimen is mild with the majority
of patients developing only mild haematological and gastro-
intestinal symptoms.
VDN The major toxicities observed in patients receiving
VDN were peripheral neuropathy (26%) and nausea and
vomiting (20%). Significant myelosuppression requiring dis-
continuation of treatment occurred in 11% of the patients.
HDM/HDBCNU The toxicity of HDM and HDBCNU
have been detailed by Cornbleet et al. (1983) and Mbidde et
al. (1988) respectively. The toxicity pattern of these drugs is
Table II Number of courses/injections given for each treatment
Number of
courses/injections VDN HDM HDBCNU BOLD
1 3 29 8 8
2 7 4 1 11
3 13 1 - 12
4 24 - 6
5 5 2
6 10 2
7+ 16 - - -
Number of patients 80 34 9 41
Table III Response of patients to treatment
Response VDN HDM HDBCNU BOLD
Complete remission 1 2 1 3
Partial remission 1 5 3 7
No change with some 14 14 1 4
improvement
No change with no 42 7 3 10
improvement
Progressive disease 22 6 1 7
Number of patients 80 34 9 31
% complete and 2.5 20.6 44.4 24.4
partial remission
95% Cl 0.3-8.7 8.7-38.1 13.7-78.9 12.3-40.4
Table IV Sites of first metastases for complete responders
Earliest mets Ist mainline treatment Mets before treatment
Visceral BOLD Visceral
Nodal HDM x 2 Nodal, local + distant
skin + visceral
Nodal HDM Nodal
Nodal VDN Nodal
Nodal HDBCNU x 2 Nodal
Nodal BOLD Nodal
Nodal BOLD Nodal
100
16
U,
0
Cu
4 -
.0
.00.Q-
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Q0
0 1 2
Years since start of treatment
Figure I The cumulative probability of survival for patients
treated with the four chemotherapy regimens. VDN;
..... HDM; --- HDBCNU; BOLD.
U 1 2
Years since start of treatment
Figure 2 a, The cumulative probability of survival for patients
treated with all regimens divided according to response or
non-response to chemotherapy. All patients. Responders;
..... Non-responders. b, The cumulative probability of survival for
patients treated with all regimens divided according to response
or non-response to chemotherapy. Excluding patients who died
within 3 months of receiving their chemotherapy. Respond-
ers;. Non-responders.
CHEMOTHERAPY FOR MALIGNANT MELANOMA 333
Table V Number (%) of patients with WHO grade 2 toxicity or more
severity recorded
VDNd HDM HDBCNU BOLD
Hb - 22 ( 65) 1 (11) 7 (17)
WC 9 (11) 34 (100) 7 (78) 9 (22)
Platelets - 34 (100) 6 (67) 13 (32)
Nausea and vomiting 16 (20) 20 ( 59) 2 (22) 6 (15)
Diarrhoea - 4 ( 12) 0 (0) 0 (0)
Peri. neuropathy 21 (26) 0 ( 0) 0 ( 0) 0 ( 0)
Hair 15 (19) 20 ( 59) 2 (22) 1 ( 2)
Others 0 34 (100)C (1 1)a I ( 2)b
aChest infection; binfection; cfever; dtoxicity recorded as just yes/no.
- not recorded.
quite different from VDN and BOLD and the side-effects are
related to the acute administration of large doses of the
drugs.
HDM is associated with grade 4 myelosuppression in all
cases and required inpatient and intensive supportive care for
4 weeks. All patients also experienced reversible hair loss.
HDBCNU is slightly less myelosuppressive (50% grade 4 and
38% grade 3 toxicity) and the duration of the myelosuppres-
sion is also shorter with less than 2 weeks in hospital.
Non-haematological toxicity includes moderate nausea and
vomiting, reversible hair loss as with HDM, and one patient
had a drug induced pneumonitis which recovered after treat-
ment with steroids.
Treatment related deaths
The number of patients who died within 1 month of receiving
one of the four treatment regimes were HDM seven,
HDBCNU one and BOLD two. Not surprisingly patients
receiving the high dose regimens fared worse and this is
related to the period of severe myelosuppression that occurs
following the administration of these drugs. The two deaths
due to the BOLD regimen were secondary to myelosuppres-
sion and sepsis.
Second line chemotherapy
After initial treatment with one of the four regimens 34
patients were treated with alternative chemotherapy for re-
lapse or failure to respond. Of the 80 patients who had
VDN, six subsequently had BOLD, seven HDM and six
HDBCNU. Of th 34 who had HDM as primary treatment,
one had BOLD and seven had VDN. In the HDBCNU
group (nine patients), one went on to have BOLD, one VDN
and one VDN followed by BOLD. Finally, of the 41 who
had BOLD as first treatment, four went on to have VDN.
The overall response rate for second line chemotherapy was
9% and there was no difference between the four treatment
groups (VDN, HDM, HDBCNU, BOLD).
Predictors of response to first mainline treatment
Logistic regression techniques were used with standard for-
ward selection methods to determine which factors were
predictive of response (CR or PR) to first mainline chemo-
therapy. The following variables were considered: age
(divided around the median age < 45 years, > 45 years),
sex, performance status (both as WHO grades 0, 1, 2 +
and as 0/1, 2 +), treatment (both as BOLD, VDN, HDM,
HDBCNU and as VDN versus not VDN), primary site (both
as head and neck, trunk, limbs, others and as limbs versus
rest), indication for treatment (asymptomatic progression,
pain, bulk of disease, other including cough, fatigue, weight
loss and a variety of other disease related symptoms), first
metastases involved nodes (yes or no), first metastases in-
volved skin (yes or no) and first metastases involved visceral
site (yes or no).
The final model selected showed that the choice of treat-
ment (VDN or not), age and primary site (limb or not)
independently significantly influenced the response rate.
Treatment with drugs other than VDN increased the chances
of response (OR= 11.6; 95% CI 2.5, 53.2; P=0.001);
patients aged under 45 had a higher chance of response
(independent of treatment) (OR= 3.4; 95% CI 1.1, 10.5;
P = 0.03); those whose primary tumour was on a limb had
an increased chance of obtaining a response (OR = 3.1; 95%
CI 1.1, 8.4; P = 0.03) to first mainline treatment.
All other variables appeared to be of no value in predicting
for response when considered either univariately or multi-
variately.
Survivalfrom first metastases
The following variables were considered in a univariate
analysis as possible prognostic factors for survival from first
metastases: age (< 45 years, > 45 years), sex, performance
status (WHO 0, 2, 2 +), primary site (head and neck, trunk,
limbs, other), indication for treatment (asymptomatic pro-
gression, pain, bulk, other), site of first metastases (nodal,
skin, visceral involvement) and treatment regimen (VDN,
HDM, HDBCNU, BOLD). Site of first metastases was
found to be a strong prognostic factor and this effect was
completely described by whether or not the site of first
metastases included visceral involvement, (log rank test
= 24.05; d.f. = 1, P< 0.0005). Whether or not the site of the
first metastases included lymph nodes or skin was not found
to be of any significant prognostic importance. The impor-
tance of site of the primary tumour, considered on four levels
(see above), did not reach conventional statistical significance
(log rank test = 6.62; d.f. = 3, P = 0.09), but some variation
between sites does appear to exist, and if we consider the
dichotomous categorisation of limbs versus rest of body then
we observed that patients whose primary tumour is situated
on a limb have a better prognosis than the others (log
rank test = 5.64; d.f. = 1; P = 0.018). Decreasing perfor-
mance status resulted in a poorer prognosis (log rank
test = 7.26; d.f. = 1, P = 0.007). Indication for treatment was
found to be of significant prognostic value (log rank test
= 11.40; d.f. = 3, P = 0.010), poorer prognosis being seen in
those patients whose indications were bulk of disease or
'other' (see above). Age and sex were not found to be of
significant prognostic value. Treatment regimen did not
influence survival from first metastases (log rank test = 1.97;
d.f. = 3, P = 0.58).
Cox proportional hazards regression analysis
The variables described above in the univariate analysis were
considered in the multivariate situation.
Survival from first metastases A final model was obtained
which included significant prognostic factors in decreasing
order of importance for visceral involvement at first meta-
stases (OR= 2.6; 95% CI 1.7, 3.9; P<0.001), performance
status (WHO grade 2 or worse: OR = 1.7; 95% CI 1.1, 2.7;
P = 0.017), indication for treatment (odds ratios are com-
pared with the risk of death in patients treated for asymp-
tomatic progression) (pain: OR = 0.96; 95% CI 0.65, 1.4;
bulk of disease: OR= 2.8; 95% CI 1.4, 5.6; 'other': OR
= 1.3; 95% CI 0.80, 2.1; heterogeneity test P = 0.029) and
primary site (limb: OR = 0.71; 95% CI 0.51, 1.0; P = 0.046).
Survival from start of treatment A final model was obtained
which included significant prognostic factors for performance
status (WHO grade 2 or worse: OR= 2.0; 95% CI 1.3, 3.1;
P = 0.003) and indication for treatment (compared with
asymptomatic progression) (pain: OR = 1.3; 95% CI 0.89,
1.9; bulk of disease: OR= 3.0; 95% CI 2.1, 6.1; 'other':
OR = 1.7; 95% CI 1.0, 2.9; heterogeneity test P = 0.001). Site
for first metastases was not found to be of any prognostic value.
If, in addition, response to treatment is considered as a
potential prognostic factor for all patients, the model
obtained included significant prognostic factors for response
status (CR + PR: OR= 2.4; 95% CI 1.4, 3.9; P<0.001),
performance status (WHO grade 2 or worse: OR = 2.0; 95%
CI 1.3, 3.0; P = 0.004) and indication for treatment (com-
pared with asymptomatic progression) (pain: OR = 1.4; 95%
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CI 0.98, 2.1; bulk of disease: OR= 3.4; 95% CI 1.7, 6.8;
'other': OR = 1.8; 95% CI 1.1, 3.1; P = 0.004). Treatment
regimen did not influence survival from treatment or survival
from first metastases on multivariate analysis.
Discussion
This study is a retrospective analysis and conclusions about
comparisons of the groups, which were not randomised, must
be drawn cautiously. Multivariate analysis provides a tool for
comparing the groups, but only allows us to correct for
known prognostic variables. Nevertheless, we believe that the
results support our view that increasing intensity of chemo-
therapy either as drug combinations or as high dose treat-
ment has not resulted in longer survival for our patients.
Our response rates for combination and high dose chemo-
therapy are higher than those of single agent vindesine. This
is in keeping with experience at other institutions. However,
our recorded response rates for VDN and BOLD are lower
than those recorded in the literature. For VDN response
rates of between 12% and 20% have been quoted (Nelimark
et al., 1983; Retsas et al., 1979; Quagliana et al., 1984) and
for BOLD combination chemotherapy response rates up to
46% are recorded (Ahn et al., 1983; Reintgen et al., 1983)
although our results are in keeping with the most recent
report with this regimen of 24% (York & Foltz, 1988).
There are two reasons why we expect our response rates
for BOLD and VDN to be lower than those from other
institutions. First we have reserved the use of chemotherapy
for a palliative role in a relatively late stage of the disease.
The median time from diagnosis of metastases to treatment
was 5.5 months. Patients with asymptomatic skin and sub-
cutaneous metastases are not given chemotherapy. Second,
we have rigorously applied response criteria using the WHO
system so that response is required at all measurable sites.
The response rates may also be reduced because of the short
duration of treatment in some patients on VDN and BOLD
(eight patients in the BOLD group received only one course
and 10 patients in VDN group received two or less courses).
This is unlikely to be an important feature because most of
those patients had progressed after their initial treatments
making subsequent response unlikely. Nevertheless, our res-
ponse rate to vindesine may have been reduced by our con-
servative use of the drug. If this is the case, then the failure
of the more intensive regimens to prolong life is even more
disappointing.
A small proportion of patients went on to receive second
line chemotherapy after failure of their initial treatment. We
have considered whether the use of the more intensive
regimens as second line treatment might have reduced the
evidence for any survival benefit in this comparison. The
small number of patients who received second line treatment,
and the very low response rate to this, suggests that this is
not the case.
There appears to be no survival advantage in the numbers
of patients studied here in the choice of the more intensive
regimens despite their association with higher response rates.
This is apparent on inspection of the survival curves and
confirmed by univariate and multivariate analyses. This situa-
tion is not uncommon in clinical oncology (Selby & McEl-
wain, 1986) especially when most responses are partial and
when complete responses tend to occur at non-life threaten-
ing sites. The factors associated with response to
chemotherapy are similar to those associated with a favour-
able natural history. The fit patient is likely to have a res-
ponse of his tumour to drugs but he would also live longer if
untreated. The association between response and survival
seems not to be a causal relationship under these circum-
stances.
The purpose of chemotherapy is wider than only to pro-
long life. Response is usually associated with symptomatic
relief and hence may improve the quality of life in some cases
although toxicity and time in hospital have to be considered.
Some symptomatic improvement was noted in patients who
failed to even achieve a partial remission and the proportion
doing so was higher in the intensive regimes.
The main goal of research into the treatment of metastatic
malignant melanoma must remain the development of new
cytotoxic or biological drugs rather than further work with
conventional agents.
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